01—Abstract
Summary
Summary of the 10-K filed February 16, 2021. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. (NASDAQ: MEDP) reported net revenue of $925.9 milliona for the year ended December 31, 2020, up $65.0 million from $861.0 million in 2019, with the filing attributing the increase primarily to strong activity in Oncology, AVAI and other uncategorized therapeutic areas.
Income from operations rose to $167.0 millionb from $127.3 million, and net income increased to $145.4 million from $100.4 million, helped by a 13.7% effective tax rate versus 19.5% in 2019. Diluted EPS was $3.84 compared with $2.67 a year earlier. The filing states that COVID-19 had a significant adverse effect on fiscal 2020, reducing trial starts and slowing new business awards, and that management expects a continued adverse impact on results, though the duration and scope of the pandemic cannot be reasonably estimated.
Net new business awards were $1,175.0 millionc in 2020 versus $1,094.4 million in 2019, and backlog grew to $1,541.7 million from $1,283.2 million, with approximately $785 million to $805 million expected to convert to net revenue in 2021. Balance sheet and cash flow were strengthened over the year: cash and cash equivalents reached $277.8 million, operating cash flow was $258.7 million, and the company had no borrowings under its $50.0 million unsecured Credit Facility. The company repurchased 1,183,095 shares for $98.3 million in 2020 and had $102.6 million remaining under its repurchase authorization.
Investors should note the concentration of ownership: CEO and founder August J. Troendle controls approximately 20.2%d of outstanding shares, and the company has never paid dividends.
02—Key points
Key Highlights
- Net revenue of $925.9 million for 2020, up $65.0 million from $861.0 million in 2019
- Income from operations of $167.0 million versus $127.3 million in 2019; net income of $145.4 million versus $100.4 million
- Diluted EPS of $3.84 for 2020 compared with $2.67 for 2019
- Net new business awards of $1,175.0 million in 2020; backlog increased to $1,541.7 million from $1,283.2 million
- Cash and cash equivalents of $277.8 million at year-end; operating cash flow of $258.7 million; no borrowings under the Credit Facility
- Share repurchases of $98.3 million (1,183,095 shares) in 2020, with $102.6 million of authorization remaining
- COVID-19 significantly adversely affected 2020 results, and the company expects a continued adverse impact; the future financial impact cannot be reasonably estimated
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2020filed February 16, 2021Financial Statements
FY2020 against FY2019
| Line item | FY2020FY2019 | Change |
|---|---|---|
| Revenue | $925.92M$860.97M | +7.5% |
| SG&A Expenses | $92.16M$95.25M | −3.2% |
| Operating Expenses | $758.88M$733.71M | +3.4% |
| Operating Income | $167.04M$127.26M | +31.3% |
| Net Income | $145.38M$100.44M | +44.7% |
| EPS (Basic) | $4.07$2.79 | +45.9% |
| EPS (Diluted) | $3.84$2.67 | +43.8% |
| Shares Outstanding (Basic) | 35.63M35.88M | −0.7% |
| Shares Outstanding (Diluted) | 37.71M37.58M | +0.4% |
05—Questions
Frequently Asked Questions
How did Medpace perform financially in 2020?
Net revenue rose 7.5% to $925.9 million from $861.0 million, driven primarily by Oncology, AVAI and other uncategorized therapeutic areas. Income from operations increased to $167.0 million and net income to $145.4 million, with diluted EPS of $3.84.
What is the outlook for backlog conversion?
Backlog was $1,541.7 million at December 31, 2020. Approximately $785 million to $805 million was expected to convert to net revenue in 2021, with the remainder expected in years after 2021. The filing cautions that backlog contracts are generally terminable without cause and may not be a meaningful predictor of future results.
How is COVID-19 affecting the business?
The filing states that the pandemic reduced trial starts and slowed new business awards, and that it had a significant adverse effect on fiscal 2020. Management believes it will have a continued adverse impact on results, but the duration and scope of the pandemic cannot be reasonably estimated. Staff reductions were implemented in some geographies.
Does Medpace have debt or significant liquidity concerns?
As of December 31, 2020, the company had no outstanding borrowings under its $50.0 million unsecured Credit Facility, with $49.8 million available for borrowing, and $277.8 million in cash and cash equivalents. Management believes these sources are sufficient to fund cash needs for the next 12 months and longer term.
Who controls Medpace and does the company pay dividends?
CEO and founder August J. Troendle controls approximately 20.2% of outstanding shares through direct and beneficial ownership, which the filing says gives him significant influence over corporate actions. The company has not paid any dividends to date and does not plan to pay cash dividends in the foreseeable future.
06—Continue